Enveric Biosciences' Losses Mount Amid R&D Push, Cash Influx

TL;DR

**ENVB is burning cash with mounting losses, relying on dilutive financing to fund R&D, making it a high-risk bet on unproven drug candidates.**

AI Summary

Enveric Biosciences, Inc. (ENVB) reported a net loss of $1,873,669 for the three months ended September 30, 2025, and a net loss of $6,577,816 for the nine months ended September 30, 2025. This represents an increase in net loss from $6,420,341 for the nine months ended September 30, 2024. The company's cash position increased to $3,757,594 as of September 30, 2025, from $2,241,026 at December 31, 2024, primarily due to $7,890,361 in financing activities, including proceeds from common stock sales and warrant exercises. Operating expenses totaled $6,580,525 for the nine months ended September 30, 2025, up from $6,458,440 in the prior year. Research and development expenses increased to $2,408,839 for the nine months ended September 30, 2025, from $1,873,873 in the same period of 2024. The company effected two reverse stock splits: a 1-for-15 split on January 27, 2025, and a 1-for-12 split on October 23, 2025, to maintain Nasdaq listing compliance. Enveric continues to focus on developing its lead candidate, EB-003, for psychiatric and neurological disorders, following the out-licensing of its EVM201 Series program in Q4 2024.

Why It Matters

Enveric's continued net losses and reliance on equity financing for operations signal high risk for investors, despite an increased cash balance. The strategic shift to focus on EB-003 and the out-licensing of the EVM201 Series could be pivotal, but success is uncertain in the highly competitive biotechnology sector. Employees face ongoing uncertainty given the company's going concern warning, while potential customers await the development of novel neuroplastogenic therapeutics. The frequent reverse stock splits highlight significant share price volatility and dilution concerns, impacting market perception and long-term shareholder value.

Risk Assessment

Risk Level: high — Enveric Biosciences has an accumulated deficit of $112,652,321 as of September 30, 2025, and operating cash outflows of $6,356,680 for the nine months ended September 30, 2025. The company explicitly states that its current cash of $3,757,594 is not sufficient to satisfy operating cash needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ENVB given the substantial doubt about its going concern status and consistent net losses. Those already invested should monitor cash burn rates and future financing activities closely, as further dilution is highly probable to sustain operations.

Financial Highlights

debt To Equity

0.26

revenue

$0

operating Margin

N/A

total Assets

$4,362,061

total Debt

$1,132,061

net Income

-$6,577,816

eps

N/A

gross Margin

N/A

cash Position

$3,757,594

revenue Growth

N/A

Key Numbers

• $112,652,321 — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• $6,577,816 — Net Loss (for the nine months ended September 30, 2025, an increase from $6,420,341 in 2024)
• $3,757,594 — Cash (as of September 30, 2025, up from $2,241,026 at December 31, 2024)
• $6,356,680 — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025)
• $7,890,361 — Net Cash Provided by Financing Activities (for the nine months ended September 30, 2025, primarily from equity sales and warrant exercises)
• 1-for-15 — Reverse Stock Split Ratio (effected on January 27, 2025)
• 1-for-12 — Reverse Stock Split Ratio (effected on October 23, 2025)
• $2,408,839 — Research and Development Expenses (for the nine months ended September 30, 2025, an increase from $1,873,873 in 2024)

Key Players & Entities

• Enveric Biosciences, Inc. (company) — registrant
• EB-003 (product) — lead drug candidate
• MycoMedica Life Sciences (company) — out-licensed EVM201 Series program to
• Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• Securities and Exchange Commission (regulator) — filing authority
• Jay Pharma Inc. (company) — wholly-owned subsidiary
• MagicMed USA, Inc. (company) — wholly-owned subsidiary
• Akos Biosciences, Inc. (company) — wholly-owned subsidiary

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $112,652,321 as of September 30, 2025. This indicates a history of substantial losses, raising concerns about long-term financial viability and the ability to achieve profitability.
• Increasing Net Loss [high — financial]: The net loss for the nine months ended September 30, 2025, was $6,577,816, an increase from $6,420,341 in the same period of 2024. This trend suggests that operational costs are outpacing revenue generation, exacerbating the company's financial challenges.
• High Operating Expenses [medium — financial]: Total operating expenses for the nine months ended September 30, 2025, were $6,580,525, a slight increase from $6,458,440 in the prior year. While R&D expenses increased to $2,408,839, the overall high level of operating expenses, relative to the company's current financial state, is a concern.
• Reliance on Financing Activities [high — financial]: The company's cash position increased due to $7,890,361 in financing activities, primarily from common stock sales and warrant exercises. This reliance on external funding indicates a lack of self-sustaining operational cash flow.
• Nasdaq Listing Compliance [high — regulatory]: Enveric Biosciences has undergone two reverse stock splits (1-for-15 on January 27, 2025, and 1-for-12 on October 23, 2025) to maintain Nasdaq listing compliance. Continued non-compliance could lead to delisting, significantly impacting liquidity and investor confidence.
• Concentration on Lead Candidate [medium — operational]: The company's focus on developing its lead candidate, EB-003, for psychiatric and neurological disorders, following the out-licensing of its EVM201 Series program, creates concentration risk. The success or failure of EB-003 will heavily influence the company's future prospects.

Industry Context

Enveric Biosciences operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics for psychiatric and neurological disorders. This field is characterized by long development cycles, significant R&D investment, and high failure rates. The industry is driven by scientific innovation, regulatory approvals, and the ability to secure substantial funding to advance drug candidates through clinical trials.

Regulatory Implications

The company's need for multiple reverse stock splits to maintain Nasdaq listing highlights the critical importance of regulatory compliance for its stock market status. Failure to meet listing requirements could lead to delisting, severely impacting liquidity and investor confidence. Furthermore, the development of new drugs is subject to stringent FDA and other global regulatory body approvals.

What Investors Should Do

1. Monitor R&D progress and clinical trial results for EB-003.
2. Assess the company's ability to secure future funding.
3. Evaluate the impact of reverse stock splits on share price stability and investor sentiment.

Key Dates

• 2025-01-27: 1-for-15 Reverse Stock Split — Executed to meet Nasdaq minimum bid price requirements, indicating potential prior non-compliance.
• 2025-10-23: 1-for-12 Reverse Stock Split — Another reverse split to maintain Nasdaq listing, highlighting ongoing challenges with share price performance.
• 2024-Q4: Out-licensing of EVM201 Series program — Shift in strategic focus towards EB-003, reducing diversification but potentially streamlining R&D efforts.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total historical losses that have not been offset by profits. (Indicates Enveric Biosciences has a significant history of operating at a loss, with $112,652,321 as of September 30, 2025.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Enveric has implemented two reverse stock splits (1-for-15 and 1-for-12) to comply with Nasdaq's minimum share price requirements.)

Additional Paid-in Capital

The amount of money a company receives from selling stock above its par value. It represents capital contributed by investors beyond the nominal value of the shares. (Shows significant capital raised through equity issuance, totaling $116,684,259 as of September 30, 2025, to fund operations.)

Net Cash Used in Operating Activities

The net amount of cash spent or used by a company's core business operations during a specific period. A negative number indicates cash is being consumed by operations. (For the nine months ended September 30, 2025, this was $6,356,680, highlighting that the company's operations are not yet generating positive cash flow.)

Year-Over-Year Comparison

Enveric Biosciences reported a net loss of $6,577,816 for the nine months ended September 30, 2025, an increase from $6,420,341 in the prior year, indicating a worsening operational performance. While cash reserves improved to $3,757,594 due to significant financing activities, total assets also grew to $4,362,061. Operating expenses saw a slight increase to $6,580,525, with a notable rise in R&D expenses to $2,408,839, reflecting continued investment in drug development.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share ENVB The Nasdaq

Filing Documents

• form10-q.htm (10-Q) — 813KB
• ex31-1.htm (EX-31.1) — 10KB
• ex31-2.htm (EX-31.2) — 10KB
• ex32-1.htm (EX-32.1) — 9KB
• 0001493152-25-023540.txt ( ) — 4144KB
• envb-20250930.xsd (EX-101.SCH) — 36KB
• envb-20250930_cal.xml (EX-101.CAL) — 44KB
• envb-20250930_def.xml (EX-101.DEF) — 129KB
• envb-20250930_lab.xml (EX-101.LAB) — 301KB
• envb-20250930_pre.xml (EX-101.PRE) — 214KB
• form10-q_htm.xml (XML) — 550KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 2 0 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 21 ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash $ 3,757,594 $ 2,241,026 Prepaid expenses and other current assets 407,946 493,558 Total current assets 4,165,540 2,734,584 Other assets: Property and equipment, net 196,521 305,777 Intangible assets, net — 42,182 Total other assets 196,521 347,959 Total assets $ 4,362,061 $ 3,082,543 LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 683,707 $ 521,747 Due to related parties — 232,891 Accrued expenses and other current liabilities 222,178 735,098 Total current liabilities 905,885 1,489,736 Commitments and contingencies (Note 9) - Mezzanine equity Series C redeemable preferred stock, $ 0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Total mezzanine equity — — Shareholders' equity Preferred stock, $ 0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $ 0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Common Stock, $ 0.01 par value, 100,000,000 shares authorized, 518,296 and 56,501 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 5,183 565 Additional paid-in capital 116,684,259 108,261,264 Accumulated deficit ( 112,652,321 ) ( 106,074,505 ) Accumulated other comprehensive loss ( 580,945 ) ( 594,517 ) Total shareholders' equity 3,456,176 1,592,807 Total liabilities, mezzanine equity, and shar

View Full Filing

View this 10-Q filing on SEC EDGAR